LIT scientists give insights in T cell therapy for clinicians
LIT scientists Dr. Astrid Holzinger, Dr. Markus Barden and Prof. Hinrich Abken give an overview on CARs, TRUCKS and the next generation of T cell therapy in the journal JATROS Hämatologie & Onkologie.
Visit the official article here!Article Details
-
Date Published
February 6, 2025
The journal JATROS Hämatologie & Onkologie is directed towards medical professionals in hematology and oncology (in German). The LIT Scientists give insights in new developments in the next generation of CARs.
Chimeric Antigen Receptor (CAR)-T cells are synthetically reprogrammed immune cells (“living drugs”) with effector functions for the targeted treatment of cancer, autoimmune diseases, and chronic inflammation. While CAR-T cells are currently being successfully used in the treatment of hematologic malignancies, the next generation of CARs additionally incorporates cytokines and their signaling pathways to enhance the T-cell response against solid tumors and recruit other immune cells.
For more information, please visit the full article in the journal “JATROS Hämatologie & Onkologie” (in German):
Astrid Holzinger, Markus Barden, Hinrich Abken. CARs, TRUCKs und die nächste Generation der T-Zell-Therapie. JATROS Hämatologie & Onkologie 2024
Dr. Astrid Holzinger, Dr. Markus Barden, Prof. Dr. Hinrich Abken (left to right)
Explore our Research Division in greater depth!
Get to know our team and find out more about our pioneering research.